Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course cemiplimab instead of radiotherapy in early-stage lung cancer
NL-OMON61249Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Recurrence-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61249.